Interferon alpha 2b treatment in an eleven-year-old boy with disseminated lymphangiomatosis.
Disseminated lymphangiomatosis is a rare disease mostly observed in children and young adults. If no surgical removal can be achieved, the prognosis is poor, especially for patients with thoracic localization and pleural effusions. Next to pleural drainage, therapeutic options include radiotherapy, local, and systemic pharmacotherapy. An 11-year-old boy presented with disseminated lymphangiomatosis involving thorax with massive pleural effusions, retroperitoneum, and bones. In immunohistochemical analysis, the tissue biopsy stained positive for vascular endothelial growth factor-receptor 3 (VEGFR-3). The patient has been treated with interferon alpha 2b for 2 years, and achieved a good clinical and radiological response.
Timke
Christian
C
Departments of Pediatrics, University of Kiel, Schwanenweg 20, Kiel, Germany. ctimke@pediatrics.uni-kiel.de
Krause
Martin F
MF
Oppermann
Hans-Conrad
HC
Leuschner
Ivo
I
Claviez
Alexander
A
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002648:Child; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008202:Lymphangioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016066:Pleural Effusion, Malignant / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011994:Recombinant Proteins; D012074:Remission Induction; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000096:biosynthesis
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D040321:Vascular Endothelial Growth Factor Receptor-3